Effects of eprosartan on serum metabolic parameters in patients with essential hypertension

Area of Science:

• Cardiology
• Pharmacology
• Metabolic Medicine

Background:

• The metabolic effects of the antihypertensive drug eprosartan are not well-documented.
• Essential hypertension management requires understanding drug impacts beyond blood pressure.
• Atherogenesis, oxidative stress, and clotting are key factors in cardiovascular disease.

Purpose of the Study:

• To evaluate the impact of eprosartan on metabolic parameters in patients with essential hypertension.
• To assess eprosartan's effects on markers of atherogenesis, oxidative stress, and clotting activity.
• To determine if eprosartan influences liver enzymes, lipid profiles, glucose homeostasis, or renal function.

Main Methods:

• An open-label, unblinded intervention study involving 40 adult patients with essential hypertension.
• Eprosartan was administered, and changes in systolic and diastolic blood pressure were measured.
• Levels of oxidative stress markers (e.g., oxidative by-products, 8-isoprostane), liver enzymes (AST, ALT), lipid profile, apolipoproteins, glucose, creatinine, uric acid, and clotting/fibrinolytic factors were assessed.

Main Results:

• Eprosartan significantly reduced systolic blood pressure by 8% and diastolic blood pressure by 13%.
• A 24% increase in the time to produce oxidative by-products was observed, indicating reduced oxidative stress.
• No significant alterations were found in 8-isoprostane levels, lipid profile, apolipoprotein levels, glucose homeostasis, creatinine, uric acid, or clotting/fibrinolytic status.

Conclusions:

• Eprosartan is an effective antihypertensive agent.
• The drug demonstrates a neutral effect on most metabolic parameters in hypertensive individuals.
• Eprosartan's primary role is blood pressure reduction with minimal impact on metabolic pathways relevant to cardiovascular risk.